Fonte: Clinical Immunology. Unidade: FMRP
Assuntos: COVID-19, TROMBOSE, FÁRMACOS, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MASTELLOS, Dimitrios C. et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clinical Immunology, v. 220, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clim.2020.108598. Acesso em: 02 nov. 2024.APA
Mastellos, D. C., Silva, B. G. P. P. da, Fonseca, B. A. L. da, Fonseca, N. P., Martins, M. A., Mastaglio, S., et al. (2020). Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clinical Immunology, 220. doi:10.1016/j.clim.2020.108598NLM
Mastellos DC, Silva BGPP da, Fonseca BAL da, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy [Internet]. Clinical Immunology. 2020 ; 220[citado 2024 nov. 02 ] Available from: https://doi.org/10.1016/j.clim.2020.108598Vancouver
Mastellos DC, Silva BGPP da, Fonseca BAL da, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy [Internet]. Clinical Immunology. 2020 ; 220[citado 2024 nov. 02 ] Available from: https://doi.org/10.1016/j.clim.2020.108598
